A phase I/II study of prexasertib in combination with irinotecan in patients with relapsed/refractory desmoplastic small round cell tumor and rhabdomyosarcoma.Emily K. Slotkin, William D. Tap, Audrey Mauguen et al.|Journal of Clinical Oncology|2022Cited by 14
A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).Bilal A. Siddiqui, Elizabeth Miller, Przemyslaw Twardowski et al.|Journal of Clinical Oncology|2025Cited by 4
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial ResultsEmily K. Slotkin, William D. Tap, Audrey Mauguen et al.|JCO oncology advances.|2025Cited by 3
P4.11D.04 A Phase 1/2 Study of REGN7075 (EGFRÃ-CD28) Combined with Cemiplimab (anti-PD-1) In NSCLC: Trial in Progress UpdateM.L. Johnson, Neil H. Segal, Eugenia Girda et al.|Journal of Thoracic Oncology|2024Cited by 0